{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:46:09Z","timestamp":1791359169834,"version":"4.3.1"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"11","funder":[{"name":"Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan","award":["#20K17087"],"award-info":[{"award-number":["#20K17087"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>\n            Background\u2003Real-world data on clinical characteristics and outcomes related to the use of different direct oral anticoagulants (DOACs) for cancer-associated venous thromboembolism (VTE) is lacking.<\/jats:p><jats:p>\n            Methods\u2003The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive patients with acute symptomatic VTE from 31 centers in Japan from January 2015 to August 2020. Our study population comprised 1,197 patients with active cancer who were divided into the edoxaban (N\u2009=\u2009643, 54%), rivaroxaban (N\u2009=\u2009297, 25%), and apixaban (N\u2009=\u2009257, 22%) groups.<\/jats:p><jats:p>\n            Results\u2003The cumulative 5-year incidence of recurrent VTE (9.3, 10.2, and 8.5%, respectively, p\u2009=\u20090.82) and all-cause death (67.5, 66.8, and 63.8%, respectively, p\u2009=\u20090.22) did not differ among the groups. Despite adjusting for confounders, the risks of recurrent VTE and all-cause death did not differ significantly among the groups. The cumulative 5-year incidence of major and clinically relevant bleeding was significantly lower in the rivaroxaban group than those in the other groups (22.6, 14.0, and 22.8%, p\u2009=\u20090.04; and 37.6, 26.8, and 38.3%, p\u2009=\u20090.01, respectively). After adjusting for confounders, in the rivaroxaban group, the risk for major bleeding was numerically lower (hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.40\u20131.01) and that of clinically relevant all bleeding was significantly lower (HR: 0.67, 95% CI: 0.48\u20130.92) than those in the edoxaban group.<\/jats:p><jats:p>\n            Conclusion\u2003The risks of recurrent VTE and all-cause death did not differ significantly among the different DOACs ; however, the risk of bleeding events could differ, with a potentially lower risk of bleeding with rivaroxaban.<\/jats:p>","DOI":"10.1055\/a-2316-5269","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T23:09:55Z","timestamp":1714432195000},"page":"1013-1023","source":"Crossref","is-referenced-by-count":8,"title":["Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2"],"prefix":"10.1055","volume":"124","clinical-trial-number":[{"clinical-trial-number":"umin000044816","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0960-0339","authenticated-orcid":false,"given":"Daisuke","family":"Sueta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Chatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriaki","family":"Inoko","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kinki University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Oi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japanese Red Cross Otsu Hospital, Otsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Otsui","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tenri Hospital, Tenri, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Ogihara","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shiga General Hospital, Moriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Usami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Saiseikai Noe Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonori","family":"Togi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Koitabashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Hiramori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Koto Memorial Hospital, Higashiomi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Shimada General Medical Center, Shimada, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takabayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Sugita Genpaku Memorial Obama Municipal Hospital, Obama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shioyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Dohke","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Kohka Public Hospital, Koka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the COMMAND VTE Registry-2 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"A J Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4137\/CMO.S18991","article-title":"Cancer-associated thrombosis: an overview","volume":"8","author":"G Elyamany","year":"2014","journal-title":"Clin Med Insights Oncol"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","article-title":"Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism","volume":"43","author":"L Girardi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref5","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"ref7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"D Schrag","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.mayocp.2019.05.035","article-title":"Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: a systematic review and network meta-analysis","volume":"94","author":"H E Fuentes","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1076029619853629","DOI":"10.1177\/1076029619853629","article-title":"Efficacy and safety of direct oral anticoagulants for risk of cancer-associated venous thromboembolism","volume":"25","author":"J Zeng","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"103074","DOI":"10.1016\/j.critrevonc.2020.103074","article-title":"Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: a systematic review and meta-analysis","volume":"154","author":"M Camilli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"J Sabatino","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.mayocp.2020.10.041","article-title":"Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis","volume":"97","author":"I B Riaz","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1007\/s00520-022-07433-4","article-title":"Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis","volume":"30","author":"S Wu","year":"2022","journal-title":"Support Care Cancer"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.medcli.2022.06.022","article-title":"Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a systematic review and Bayesian network meta-analysis","volume":"160","author":"H Ning","year":"2023","journal-title":"Med Cl\u00edn (Barc)"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis","volume":"6","author":"T Fujisaki","year":"2024","journal-title":"JACC Cardiooncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2023.08.007","article-title":"Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants","volume":"118","author":"K Kaneda","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.12.016","article-title":"Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMAND VTE Registry-2","volume":"234","author":"R Chatani","year":"2024","journal-title":"Thromb Res"},{"issue":"9162","key":"ref18","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","article-title":"Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)","volume":"353","author":"S Z Goldhaber","year":"1999","journal-title":"Lancet"},{"issue":"15","key":"ref19","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2316-5269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:26:03Z","timestamp":1730823963000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2316-5269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2316-5269","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,29]]},"published":{"date-parts":[[2024,4,29]]}}}